GlassScriptPhysician profile
Jennifer Vasquez
NPI 1316207392
$3,863.82
in general payments reported to CMS, 2019-2025
26 companies · $844 in 2025
The $844 reported for 2025 was more than what 94% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $702 · 2022: $902 · 2023: $394 · 2024: $1,022 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,259.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $538.38 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $475.20 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $310.75 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $290.70 | 2021-2024 | |
| Astellas Pharma US INC | $272.41 | 2022-2024 | Veozah |
| Avion Pharmaceuticals | $219.85 | 2022 | |
| Exeltis, USA INC. | $181.53 | 2022-2025 | Slynd, Twirla |
| Pfizer INC. | $179.42 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $156.53 | 2024 | Spravato |
| Paratek Pharmaceuticals, INC. | $143.01 | 2025 | Nuzyra |
| Agile Therapeutics, INC. | $138.84 | 2021-2024 | Twirla |
| Xeris Pharmaceuticals, INC. | $123.83 | 2025 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $122.19 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $122.12 | 2022-2025 | Rexulti |
| Lexicon Pharmaceuticals, INC. | $115.21 | 2024 | Inpefa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $86.12 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $76.57 | 2021-2023 | Gardasil 9 |
| Therapeuticsmd, INC. | $64.00 | 2021 | |
| Organon LLC | $53.94 | 2021-2024 | |
| Exact Sciences Corporation | $50.13 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $32.31 | 2024-2025 | Mounjaro, Zepbound |
| Sumitomo Pharma America, INC. | $24.73 | 2024 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.68 | 2024 | Jardiance |
| Hologic Sales and Service, LLC | $22.68 | 2025 | Thinprep 2000 Processor, Aptima |
| Axogen | $21.35 | 2025 | |
| Edwards Lifesciences Corporation | $17.34 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Vasquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.